Odyssey Therapeutics, Inc.
ODTXNasdaqCIK 1882782HealthcareFiscal year ends Dec 31
Latest reported revenue, Q2 FY2026$0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.Latest quarter: Q2 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenue$0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Report this figureSign changed from a year earlier - Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
- Diluted EPS−$1.74Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.74 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Report this figure+94.1% on a year earlier - Free cash flow−$34.7mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$34.5m. XBRL concept
us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-335822. Derived: 6-month figure less the 3-month figure.Capital expenditure: $186.0k. XBRL conceptus-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-335822. Derived: 6-month figure less the 3-month figure.Report this figure−1.2% on a year earlier
Last eight quarters
Full statements| Line item | Unit | period not labelled2025-03-31 | period not labelled2025-06-30 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|
| Revenue | $m | 1.9Revenue, period not labelled, three months to 2025-03-31$1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Report this figure | 1.0Revenue, period not labelled, three months to 2025-06-30$959.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Report this figure | 0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Report this figure | 0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | (2041.7%)Operating margin, period not labelled, three months to 2025-03-31. operating income / revenueOperating income: −$39.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Report this figure | (4371.3%)Operating margin, period not labelled, three months to 2025-06-30. operating income / revenueOperating income: −$41.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Revenue: $959.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Report this figure | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Net margin | % | (2003.9%)Net margin, period not labelled, three months to 2025-03-31. net income / revenueNet income: −$38.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Revenue: $1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Report this figure | (4299.8%)Net margin, period not labelled, three months to 2025-06-30. net income / revenueNet income: −$41.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Revenue: $959.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Report this figure | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Diluted EPS | $ per share | (39.37)Diluted EPS, period not labelled, three months to 2025-03-31−$39.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Report this figure | (29.54)Diluted EPS, period not labelled, three months to 2025-06-30−$29.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Report this figure | (6.77)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$6.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Report this figure | (1.74)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-335822.Report this figure | |
| Free cash flow | $m | (39.5)Free cash flow, period not labelled, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$38.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Capital expenditure: $927.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Report this figure | (34.3)Free cash flow, period not labelled, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$34.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-335822. Derived: 6-month figure less the 3-month figure.Capital expenditure: $29.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-335822. Derived: 6-month figure less the 3-month figure.Report this figure | (41.2)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$41.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Capital expenditure: $148.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-06-17, accession 0001193125-26-274290.Report this figure | (34.7)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$34.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-335822. Derived: 6-month figure less the 3-month figure.Capital expenditure: $186.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-335822. Derived: 6-month figure less the 3-month figure.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| FMR LLC | 2026-06-30 | $96.9m | 5,179,262 | New+5,179,262 | |
| SR One Capital Management, LP | 2026-06-30 | $71.0m | 3,794,883 | New+3,794,883 | |
| TPG GP A, LLC | 2026-06-30 | $69.0m | 3,690,146 | New+3,690,146 | |
| LIGHTSPEED MANAGEMENT COMPANY, L.L.C. | 2026-06-30 | $67.5m | 3,608,443 | New+3,608,443 | |
| ORBIMED ADVISORS LLC | 2026-06-30 | $56.2m | 3,001,198 | New+3,001,198 | |
| Sanofi | 2026-06-30 | $37.3m | 1,991,918 | New+1,991,918 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2026-06-30 | $19.6m | 1,046,139 | New+1,046,139 | |
| Sands Capital Alternatives, LLC | 2026-06-30 | $16.4m | 875,000 | New+875,000 | |
| HHLR ADVISORS, LTD. | 2026-06-30 | $15.6m | 831,656 | New+831,656 | |
| General Catalyst Group Management, LLC | 2026-06-30 | $15.2m | 810,272 | New+810,272 |
Recent filings
All 69 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2011:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-425684 |
| 2026-09-0923:10 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-385477 |
| 2026-08-0623:00 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-335822 |
| 2026-08-0411:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-331512 |
| 2026-06-2312:45 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-278581 |
| 2026-06-1720:45 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-274290 |
| 2026-06-1720:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-274291 |
| 2026-05-1822:29 ET | SCHEDULE 13D | Ownership report, active investor | 0001072613-26-000468 |
| 2026-05-1820:06 ET | SCHEDULE 13D | Ownership report, active investor | 0001999371-26-011002 |
| 2026-05-1520:08 ET | SCHEDULE 13D | Ownership report, active investor | 0001193125-26-226695 |
Latest annual report
No annual report is in coverage for this company.
Forecast league
Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter
About the filer
- CIK
- 1882782
- Tickers
- ODTX
- Exchange
- Nasdaq
- SIC code
- 2836 Biological Products, (No Diagnostic Substances)
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- DE
- Filer category
- <br>Emerging growth company
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.